ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,287.30
0.07%
Dow Jones
44,910.65
0.42%
Gold vs US Dollar
2,649.87
0.00%
Brent Oil
71.98
-0.08%
Bitcoin
96,816.90
-0.69%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Sigilon Therapeutics Inc (SGTX)

  7. Sigilon Therapeutics Inc (SGTX) News

Sigilon Therapeutics (SGTX)

Sigilon Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SGTX
DateTimeSourceHeadlineSymbolCompany
21/08/202312:22Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:SGTXSigilon Therapeutics Inc
16/08/202304:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SGTXSigilon Therapeutics Inc
14/08/202311:25PR Newswire (US)Lilly Completes Acquisition of Sigilon TherapeuticsNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202320:28Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202320:26Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202320:24Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202320:22Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202320:20Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202320:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202320:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202320:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202320:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGTXSigilon Therapeutics Inc
10/08/202312:31Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:SGTXSigilon Therapeutics Inc
07/08/202312:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SGTXSigilon Therapeutics Inc
01/08/202320:06Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:SGTXSigilon Therapeutics Inc
27/07/202320:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGTXSigilon Therapeutics Inc
24/07/202323:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGTXSigilon Therapeutics Inc
18/07/202320:03Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:SGTXSigilon Therapeutics Inc
13/07/202312:18Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:SGTXSigilon Therapeutics Inc
29/06/202311:35Dow Jones NewsEli Lilly to Acquire Sigilon TherapeuticsNASDAQ:SGTXSigilon Therapeutics Inc
29/06/202311:04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SGTXSigilon Therapeutics Inc
29/06/202311:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SGTXSigilon Therapeutics Inc
29/06/202310:57Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:SGTXSigilon Therapeutics Inc
29/06/202310:45PR Newswire (US)Lilly to Acquire Sigilon TherapeuticsNASDAQ:SGTXSigilon Therapeutics Inc
22/05/202320:38Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SGTXSigilon Therapeutics Inc
22/05/202320:21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SGTXSigilon Therapeutics Inc
22/05/202320:21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SGTXSigilon Therapeutics Inc
22/05/202320:21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SGTXSigilon Therapeutics Inc
22/05/202320:21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SGTXSigilon Therapeutics Inc
22/05/202320:21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SGTXSigilon Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SGTX

Your Recent History

LSE
POS
Plexus
LSE
SYME
Supply@me Capital
LSE
ALBA
Alba Mineral Resources
LSE
ZED
Zenova
LSE
SCE
Surface Transforms
LSE
BGEO
Bank Of Georgia
LSE
GGP
Greatland Gold
LSE
PREM
Premier African Minerals
LSE
BOO
Boohoo
LSE
VEL
Velocity Composites
LSE
LLOY
Lloyds Banking
LSE
BKS
Beeks Financial Cloud
LSE
AV.
Aviva
LSE
JSE
Jadestone Energy
LSE
GAW
Games Workshop
LSE
MNL
Manchester & London Inve...
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    BLACK FRIDAY

    ADVFN

    Celebrating 25 years Est 1999-2024

    Save up to 50%* for Silver

    1 year 30%, 2 years 40% and *3 years 50%

    *Across 3 years £903.96 only £451.98